Payment Processing for Peptides and Pharmaceuticals: Where Quadropay Stands

High-risk sectors like peptides and pharmaceuticals are notoriously difficult to secure reliable payment processing for. Many providers either avoid the space entirely or apply a single blanket policy across very different types of business. At Quadropay, we take a more considered, risk-based approach — one that reflects the real differences between merchant models in this space.

Here's a clear breakdown of where we can, and can't, currently support merchants in the peptide and pharmaceutical sectors.

B2C RUO Peptide Sales: Not Currently Supported

Quadropay does not offer payment processing to merchants selling Research Use Only (RUO) peptides directly to consumers (B2C). RUO peptides are manufactured and labelled for laboratory and research purposes only, not for human consumption. Selling them directly to individual consumers carries elevated regulatory, reputational, and chargeback risk that sits outside our current underwriting appetite.

If your business operates in this space, we are, at this time, unable to offer onboarding.

B2B Peptide Merchants: Supported

Where peptides are sold business-to-business — for example, to laboratories, research institutions, contract manufacturers, or other legitimate commercial entities — Quadropay is able to consider applications for our full suite of processing services. B2B peptide transactions typically carry a materially different risk profile: buyers are verifiable businesses, order volumes and patterns are more predictable, and end-use is easier to substantiate through proper documentation.

Merchants in this category will still be required to go through our standard due diligence process, including verification of licensing, supply chain documentation, and buyer-type controls.

B2B and B2C Pharmaceutical Merchants: Supported

Quadropay also supports both B2B and B2C pharmaceutical merchants, provided they meet our compliance and licensing requirements. This includes businesses supplying pharmaceutical products to other businesses (wholesalers, clinics, pharmacies) as well as those selling directly to consumers, such as online and bricks-and-mortar pharmacies operating within the relevant regulatory framework.

For all pharmaceutical merchants, we require evidence of appropriate licensing and regulatory registration (for example, with the MHRA or equivalent body in the relevant jurisdiction), clear product sourcing, and robust compliance controls.

Our Full Suite of Services

For eligible merchants in these categories, Quadropay offers our complete range of payment services, including:

• Card acquiring and payment gateway integration
• Recurring and subscription billing support
• Multi-currency processing
• Fraud and chargeback management tools
• Dedicated risk and compliance support throughout onboarding and beyond

Why We Take This Approach

Payment processors that don't differentiate between merchant models in high-risk categories tend to either take on excessive risk or shut the door on legitimate businesses unnecessarily. Our approach is designed to strike a balance: supporting genuine B2B and pharmaceutical businesses with proper compliance in place, while staying disciplined about categories — like B2C RUO peptide sales — that currently fall outside our risk appetite.

Get in Touch

If your business operates in the B2B peptide space, or as a B2B or B2C pharmaceutical merchant, and you'd like to discuss payment processing options, we'd be glad to hear from you.

This article is provided for general informational purposes only and does not constitute an offer to provide services. All merchant applications are subject to Quadropay Ltd's full legal, regulatory, and compliance checks, including Know Your Business (KYB), Know Your Customer (KYC), and anti-money laundering (AML) checks. Quadropay Ltd's risk appetite and policies are subject to change without notice and are assessed on a case-by-case basis. This article does not constitute legal, financial, or regulatory advice.